Specifics:
Treatment Type:
Dual 5-alpha Reductase Inhibitor
Testing Progress:
Approved for Benign Prostatic Hyperplasia (BPH)
Phase III trials for hair loss believed resumed – Supplemental New Drug Application for Hair loss may be submitted to FDA
Clinical Results:
Much greater and longer inhibition of DHT than Propecia in early testing.
Notes:
The big question will be is it better than Propecia and whether side effects will be greater or more serious. Currently approved form will be a 0.5 mg soft gel.
